Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes
mellitus patients on oral glucose lowering agents, and naive to incretinomimetic.
Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and
arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day
changes in insulin secretion and insulin sensitivity.